Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times of Nebraska.
Press releases published on August 25, 2025
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
GlobeNewswire
·
August 25, 2025
Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmology Sebastian Wolf, M.D …
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
GlobeNewswire
·
August 25, 2025
Total equity and debt raising of ~$90 million provides runway to 2H 2027 Strong support from existing and new investors including SPRIM Global Investments Funds will be used to scale-up production of needle-free vaccination delivery technology Founding CEO …
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
GlobeNewswire
·
August 25, 2025
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) …
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
GlobeNewswire
·
August 25, 2025
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to …
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
GlobeNewswire
·
August 25, 2025
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports …
Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis
GlobeNewswire
·
August 25, 2025
Saint Herblain (France), le 25 août, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA) a suspendu la licence d’IXCHIQ®, …
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
GlobeNewswire
·
August 25, 2025
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi …
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
GlobeNewswire
·
August 25, 2025
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle Une nouvelle structure du Conseil qui reflète une représentation équilibrée et proportionnée des …
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
GlobeNewswire
·
August 25, 2025
- Expanding opportunities for organ transplantation worldwide and contributing to the advancement of transplant medicine - OXFORD, United Kingdom and MADISON, N.J., Aug. 24, 2025 (GLOBE NEWSWIRE) -- Terumo Corporation (TSE: 4543, “Terumo”) today announced …
HUTCHMED Announces Appointment of Acting Chief Executive Officer
GlobeNewswire
·
August 25, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his …